The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
Open accessAbstract
A few years after the foundation of the British Pharmacological Society, monoamine oxidase (MAO) was recognized as an enzyme of crucial interest to pharmacologists because it catalyzed the major inactivation pathway for the catecholamine neurotransmitters, noradrenaline, adrenaline and dopamine (and, later, 5‐hydroxytryptamine, as well). Within the next decade, the therapeutic value of inhibitors of MAO in the treatment of depressive illness was established. Although this first clinical use exposed serious side effects, pharmacological interest in, and investigation of, MAO continued, resulting in the characterization of two isoforms, MAO‐A and ‐B, and isoform‐selective inhibitors. Selective inhibitors of MAO‐B have found a therapeutic role in the treatment of Parkinson's disease and further developments have provided reversible inhibitors of MAO‐A, which offer antidepressant activity without the serious side effects of the earlier inhibitors. Clinical observation and subsequent pharmacological analysis have also generated the concept of neuroprotection, reflecting the possibility of slowing, halting and maybe reversing, neurodegeneration in Parkinson's or Alzheimer's diseases. Increased levels of oxidative stress in the brain may be critical for the initiation and progress of neurodegeneration and selective inhibition of brain MAO could contribute importantly to lowering such stress. There are complex interactions between free iron levels in brain and MAO, which may have practical outcomes for depressive disorders. These aspects of MAO and its inhibition and some indication of how this important area of pharmacology and therapeutics might develop in the future are summarized in this review. British Journal of Pharmacology (2006) 147, S287–S296. doi:10.1038/sj.bjp.0706464
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationSome observations upon a new inhibitor of monoamine oxidase in brain tissue
Johnston, J. P. (1968) · Biochemical Pharmacology · doi:10.1016/0006-2952(68)90066-x · Cited by 1,578
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Self-citationThe therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Self-citationHeikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
Some puzzling pharmacological effects of monoamine oxidase inhibitors.
Knoll, J. E., & Magyar, K. (1972) · PubMed · Cited by 560
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551
Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B. H., Hars, V., & Marton, J. (1985) · Journal of Neural Transmission · doi:10.1007/bf01245973 · Cited by 436
Self-citationMulti-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Self-citationBirkmayer, W., Riederer, P., Youdim, M. B. H., & Linauer, W. (1975) · Journal of Neural Transmission · doi:10.1007/bf01253131 · Cited by 363
Self-citationGr�nblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., Li, J., Ravid, R., Roggendorf, W., Riederer, P., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0212-1 · Cited by 356
Self-citationYoudim, M. B. H., Gross, A., & Finberg, J. P. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703826 · Cited by 342
Self-citationWilliams, C. H. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90626-1 · Cited by 314
Riederer, P., & Youdim, M. B. H. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb01747.x · Cited by 245
Self-citationMoclobemide: Therapeutic Use and Clinical Studies
Bonnet, U. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00245.x · Cited by 227
Zheng, H., Gal, S., Weiner, L. M., Bar‐Am, O., Warshawsky, A., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03340.x · Cited by 214
Self-citationGal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185
Self-citationYoudim, M. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00103-7 · Cited by 160
Self-citationMechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
Mandel, S., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.027 · Cited by 157
Self-citationGREEN, A. R., Mitchell, B., Tordoff, A. F. C., & Youdim, M. B. H. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07506.x · Cited by 146
Self-citationBiochemistry and pharmacology of moclobemide, a prototype RIMA
Haefely, W. E., Burkard, W. P., Cesura, A. M., Kettler, R., Lorez, H. P., Martin, J. R., Richards, J. G., Scherschlicht, R., & Prada, M. D. (1992) · Psychopharmacology · doi:10.1007/bf02246225 · Cited by 110
TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B
Finberg, J. P. M., Tenne, M., & Youdim, M. B. H. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16772.x · Cited by 103
Self-citationMendlewicz, J., & Youdim, M. B. H. (1983) · The British Journal of Psychiatry · doi:10.1192/bjp.142.5.508 · Cited by 101
Self-citationHuman Platelet Monoamine Oxidase Activity in Iron-Deficiency Anaemia
Moussa, B. H., Woods, H. F., Mitchell, B. D., Smith, A. D., & Callender, S. T. (1975) · Clinical Science · doi:10.1042/cs0480289 · Cited by 82
Pharmacotherapy of social phobia
Davidson, J. R. T. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.7.x · Cited by 69
Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background
Yamamoto, M. (2001) · Journal of Neurology · doi:10.1007/pl00022917 · Cited by 64
Youdim, M. B. H., Maruyama, W., & Naoi, M. (2005) · Drugs of today · doi:10.1358/dot.2005.41.6.893613 · Cited by 62
Self-citationBiogenic Monoamine Metabolism and Functional Activity in Iron‐Deficient Rats: Behavioural Correlates
Youdim, M. B. H., & Green, A. R. (1977) · Novartis Foundation symposium · doi:10.1002/9780470720325.ch10 · Cited by 55
Self-citationFinberg, J. P. M., & Youdim, M. B. H. (1985) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1985.tb08891.x · Cited by 45
Self-citationNeuroprotection by Rasagiline: A New Therapeutic Approach to Parkinson's Disease?
Blandini, F. (2005) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00269.x · Cited by 38
Bottlaender, M., Dollé, F., Guenther, I., Roumenov, D., Fuseau, C., Bramoullé, Y., Curet, O., Jegham, J., Pinquier, J., George, P. G., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046953 · Cited by 32
Colzi, A., D'Agostini, F., Cesura, A. M., Borroni, E., & Prada, M. D. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38112-7 · Cited by 27
Mutational Analysis of the Serotonergic System: Recent Findings Using Knockout Mice
Gingrich, B. S. P. J. A. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007023339003 · Cited by 20
Cited by
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Self-citationOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
The Thioredoxin System as a Therapeutic Target in Human Health and Disease
Mahmood, D. F. D., Abderrazak, A., El Hadri, K., Simmet, T., & Rouis, M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4757 · Cited by 305
MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
Mallajosyula, J. K., Kaur, D., Chinta, S. J., Rajagopalan, S., Rane, A., Nicholls, D. G., Di Monte, D. A., Macarthur, H., & Andersen, J. K. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001616 · Cited by 286
Striatal mechanisms underlying movement, reinforcement, and punishment
Kravitz, A. V., & Kreitzer, A. C. (2012) · Physiology · doi:10.1152/physiol.00004.2012 · Cited by 224
Metadata
- Authors
- Youdim, M. B. H., & Bakhle, Y. S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 147
- Issue
- S1
- Pages
- S287-96
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1549819404
- Cited by
- 643
- References
- 34
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.